Oric Pharmaceuticals Business Summary

Oric Pharmaceuticals, Inc. (ORIC) is a clinical-stage biopharmaceutical company that operates on a pre-revenue business model, primarily generating capital through strategic collaborations, equity financing, and private placements. The company functions as a single operating segment focused on the discovery and development of small molecule therapies designed to overcome therapeutic resistance in cancer, a mission encapsulated by its name (Overcoming Resistance In Cancer). Its primary value drivers are its lead clinical assets: rinzimetostat (ORIC-944), a PRC2 inhibitor for metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant EGFR/HER2 inhibitor for non-small cell lung cancer. ORIC competes directly with oncology-focused firms such as Erasca, Arcellx, and Loxo Oncology (Eli Lilly), distinguishing itself through a specialized focus on the biological mechanisms of drug resistance rather than broad-spectrum cytotoxic or first-line targeted therapies. The company was founded by a distinguished team of oncology experts, including Richard Heyman, PhD (co-founder of Aragon and Medivation), Charles Sawyers, MD (co-developer of Gleevec and Xtandi), and Scott Lowe, PhD (Chair of Cancer Biology at Memorial Sloan Kettering). Leadership is currently spearheaded by President and CEO Jacob M. Chacko, MD, formerly the CFO of Ignyta, and Chief Technical Officer Kevin Brodbeck, PhD, who joined in early 2026 from Deciphera Pharmaceuticals to lead late-stage clinical manufacturing. The executive team also includes CFO Dominic Piscitelli and Chief Business Officer Matthew Panuwat. ORIC is backed by a high-pedigree roster of institutional investors and strategic partners, including Pfizer, Bayer, Johnson & Johnson (Janssen), SR One, and Viking Global Investors, with a board of directors featuring industry veterans from Madrigal and Architect Therapeutics.